News >

Checkpoint Inhibitors, TKIs, and Novel Agents Poised to Enter Liver Cancer Treatment Paradigm

Gina Columbus @ginacolumbusonc
Published: Tuesday, Dec 19, 2017

Dr Ghassan Abou-Alfa

Ghassan Abou-Alfa, MD
Prior to 2017, the hepatocellular carcinoma (HCC) space had little movement in therapeutic advancements beyond standard sorafenib (Nexavar).

State of the Science SummitTM on Gastrointestinal Cancers, Abou-Alfa, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed what he sees coming down the pike in HCC with regard to novel agents, including CAR T-cell therapy, and the burgeoning questions with optimal sequencing of these treatments.

OncLive®: A lot has been happening in this field as of late. What would you like to highlight?

Abou-Alfa: It has been great to be here tonight for the State of the Science SummitTM, and it was a great honor to talk about primary liver cancer, especially this year. This has been an incredible year and positive time regarding our therapies for [patients with] liver cancer. As we both know, liver cancer had only one therapy, sorafenib, that was approved by the FDA almost 10 years ago. If anything, we have been trying for the past 10 years to see how we can improve on the outcome of sorafenib either by trying different things—by going into combination therapies, or even looking at second-line therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication